• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Aptivus (tipranavir) 250 mg capsules and 100 mg/mL oral solution

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- June 2009

 

Summary View

 

DRUG INTERACTIONS

Table 4 Updated
  • Fusion Inhibitors: Enfuvirtide- AT steady state, tipranavir trough concentrations were approximately 45% higher in patients co-administered enfuvirtide in the Phase 3 trials.  The mechanism for this increase is not known.  Dose adjustments are not recommended.
  • Calcium Channel Blockers- Caution is warranted and clinical monitoring of patient is recommended.
  • Buprenorphine/naloxone- Aptivus/ritonovir did not result in changes in the clinical efficacy of buprenorphine/naloxone.  Compared to historical controls tipranavir Cmin was decreased approximately 40 % with this combination.  Dose adjustments can not be recommended.